Biocon Share Price Extended Gain For 2nd Straight Day: Rose Over 3% Intraday

Biocon share price extended the gains for the second straight day with an increase of over 3% on January 14, 2025. Biocon share price touched the day high of ₹382.05 at 10:50 AM after opening at ₹370.00. The gain in Biocon share price came after the previous day’s gain of over 1%. Following the increase, Biocon share price is currently trading near its 52-week high of ₹395.65.

Biocon Latest Business Updates

• Biocon Biologics Limited, a subsidiary of Biocon Limited, has once again been recognised as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management), the world’s leading intellectual property (IP) publication. This marks the 8 consecutive year that both Biocon and its subsidiary Biocon Biologics have earned a spot on this prestigious list.
• Biocon Biologics, a fully integrated global biosimilars company, is also proud to share the progress of its ongoing ‘Embedding Specialist Nurses in Diabetes Care’ project. This initiative, a collaboration with Diabetes Africa and St. Paul’s Hospital Millennium Medical College in Ethiopia, is focused on enhancing diabetes care. The first phase of this multi-year project, supported by Biocon Biologics, has successfully engaged key stakeholders in Ethiopia’s diabetes ecosystem to develop a scalable model for upskilling nurses into diabetes specialists, to improve diabetes care across the country.

Biocon Q2FY25 Financial Performance

Biocon Group’s Q2FY25 financial and operational performance lays a strong foundation for continued improvement in the 2HFY25. Operating Revenues of ₹3,590 Cr show a year-on-year growth of 8% on a like-for-like basis, while core EBITDA and EBITDA margins remain healthy at 28% and 20%, respectively. The Biosimilars business delivered a strong performance, with a 19% increase in like-for-like revenue, driven by significant market share gains in its US Oncology and Insulin franchises.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.